Moleculin Biotech is trading at $0.41 (-5.51%), in line with biotech-sector weakness and broader equity declines. - Biotech ETF XBI was down 2.01% in the provided session context. - The company was scheduled to present its oncology pipeline at the Maxim Growth Summit on October 14; available information does not establish the presentation as the cause of the drop, and no clear company-specific catalyst was identified.